经全体监事共同推举，公司监事黄健生先生担任本次会议主持人。本次会议 应到监事 3 名，实到 3 名。本次会议的召开符合《公司法》《公司章程》及有关 法律、法规的规定。 二、监事会会议审议情况 | 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2023-080 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 上海雪榕生物科技股份有限公司 第五届监事会第一次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 上海雪榕生物科技股份有限公司（以下简称"公司"）于 2023 年 8 月 23 日召开了 2023 年第三次临时股东大会，选举产生了公司第五届监事会非职工代 表监事 2 人，与公司职工代表大会选举产生的职工代表监事 1 人共同组成公司第 五届监事会。经全体监事一致同意豁免本次临时监事会通知时限，第五届监事会 第一次会议通知于当日以现场告知的方式发出。第五届监事会第一次会议于同日 以现场投票表决的方式在公司会议室举行。 三、备查文件 1、公司第五届监事会第一 ...

| | | 2023 年 8 月 18 日 上海雪榕生物科技股份有限公司 董事会 上海雪榕生物科技股份有限公司 关于独立董事候选人取得独立董事资格证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"）于2023年7月31日召开 了第四届董事会第五十一次会议，审议通过了《关于公司董事会换届选举暨第五 届董事会独立董事候选人提名的议案》。经董事会提名委员会进行资格审核，公 司董事会提名李丹蒙先生为公司第五届董事会独立董事候选人，任期自公司股东 大会审议通过之日起至公司第五届董事会届满之日止。 截至公司2023年第三次临时股东大会通知发出之日，李丹蒙先生尚未取得深 圳证券交易所认可的独立董事资格证书。根据深圳证券交易所的有关规定，李丹 蒙先生已书面承诺参加最近一期独立董事培训并取得深圳证券交易所认可的独 立董事资格证书。 近日，公司董事会收到李丹蒙先生的通知，李丹蒙先生已按照相关规定参加 了深圳证券交易所举办的上市公司独立董事任前培训（线上），并取得了深圳证 券交易所创业企业培训中心颁发的《上市公司独立董事资格证 ...

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2023-075 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 关于公司控股股东的一致行动人股份减持计划到期的公告 公司股东浙江银万斯特投资管理有限公司-银万华奕 1 号私募证券投资基金保证 向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 上海雪榕生物科技股份有限公司（以下简称"公司"）于 2023 年 1 月 16 日在 巨潮资讯网上披露了《关于公司控股股东的一致行动人股份减持计划的预披露公 告》（公告编号：2023-003）。持有公司股份 22,100,000 股的股东浙江银万斯特 投资管理有限公司-银万华奕 1 号私募证券投资基金（为公司控股股东杨勇萍先 生的一致行动人，以下简称"银万华奕 1 号"）计划通过大宗交易、集中竞价等方 式减持不超过公司股份 15,000,000 股（即不超过公司总股本的 2.98%）。公司于 2023 年 4 月 28 日披露《关于控股股东、实际 ...

证券代码：300511 证券简称：雪榕生物 上海雪榕生物科技股份有限公司 投资者关系活动记录表 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及 人员姓名 通过深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn） "云访谈"栏目参与本次业绩说明会的广大投资者 时间 2023年5月10日（周三）下午15:00-17:00 地点 深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn）"云 访谈"栏目 上市公司接待人 员姓名 1、董事长、总经理：杨勇萍先生 2、董事会秘书：顾永康先生 3、独立董事：黄建春先生 4、保荐代表人：聂晓春女士 投资者关系活动 主要内容介绍 投资者提出的问题及公司回复情况： 1、公司之前发行的 5.85 亿元可转债募资项目进展如何？目前 离可转债到期尚有时间，公司在推动转股方面将做哪些工作？ 近期是否考虑下修转股价？公司是否欢迎中小投资者来贵行实 地调研与高管互动，如近期有调研需求的话，采取何种方式与 董秘或证代预约。 答：尊敬的投资者，您好。可转 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥842,411,282.63, representing a 46.27% increase compared to ¥575,916,010.18 in the same period last year[6] - Net profit attributable to shareholders was ¥222,710,908.61, a significant increase of 288.02% from ¥57,397,068.93 year-on-year[6] - The net cash flow from operating activities surged by 715.55% to ¥295,287,662.74, compared to ¥36,207,316.24 in the previous year[6] - Basic earnings per share increased to ¥0.45, up 246.15% from ¥0.13 in the same period last year[6] - Operating profit surged to ¥233,488,096.74, up 311.5% from ¥56,800,357.57 year-over-year[25] - Total comprehensive income for the period was ¥233,334,584.76, compared to ¥60,304,994.90 in the same quarter last year[26] - The company reported a net profit of approximately 565.11 million CNY in Q1 2023, compared to 342.40 million CNY at the beginning of the year, reflecting strong profitability growth[23] Asset and Equity Growth - Total assets at the end of the reporting period were ¥4,250,354,252.97, reflecting a 4.38% increase from ¥4,072,032,071.35 at the end of the previous year[6] - As of the end of Q1 2023, the company's total assets reached approximately 4.25 billion CNY, an increase from 4.07 billion CNY at the beginning of the year[22] - The company's total equity increased to approximately 1.87 billion CNY from 1.63 billion CNY at the beginning of the year, showing growth in shareholder value[23] Cash Flow and Liquidity - Cash flow from operating activities generated ¥295,287,662.74, compared to ¥36,207,316.24 in the previous year, marking a substantial improvement[29] - The company reported a net cash inflow from investment activities of ¥148,277,051.27, reversing a net outflow of ¥102,660,123.39 in the prior period[29] - The company's cash and cash equivalents increased to approximately 700.87 million CNY from 363.82 million CNY at the beginning of the year, reflecting a significant liquidity improvement[22] - The cash and cash equivalents at the end of the period totaled ¥693,290,300.17, down from ¥708,021,120.92 at the end of the previous period[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,204[14] - The largest shareholder, Yang Yongping, holds 21.39% of the shares, totaling 107,606,850 shares, with 4,500,000 shares pledged[14] - Zhejiang Yinwan Siter Investment Management Co., Ltd. holds 22,100,000 shares, representing a 4.39% stake[14] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder having a substantial influence[15] - The total number of restricted shares at the beginning of the period was 94,833,144, with no new restrictions added during the reporting period[18] - Yang Yongping's restricted shares remain at 80,705,137, locked due to executive restrictions[17] - The company has no preferred shareholders or related party transactions among the top shareholders[16] - The company is focused on maintaining shareholder stability and has established agreements among major shareholders to ensure coordinated actions[15] - There are no changes in the number of restricted shares for departing directors during this quarter[17] - The company continues to emphasize its commitment to corporate governance and shareholder rights[18] Investment and Expansion - The company established a wholly-owned subsidiary in Guangxi with a total investment of over 650 million CNY for a modern agricultural park project with an annual output of 195,000 tons of edible mushrooms[20] - A new subsidiary was set up in Jiangsu for a project with a total investment of 1.2 billion CNY, including a phase one investment of 1 billion CNY for a daily production of 200 tons of enoki mushrooms and related products[21] - The company has a long-term investment strategy, as evidenced by the establishment of new subsidiaries and significant capital investments in modern agricultural projects[20][21] - The company is focused on expanding its market presence through strategic investments and new product development initiatives[20][21] Cost and Expense Management - The company's total operating costs rose to ¥611,504,827.66, an increase of 16.6% from ¥524,517,329.91 in the previous period[25] - Research and development expenses slightly increased to ¥1,860,518.88 from ¥1,826,764.99, indicating continued investment in innovation[25] - The company experienced a 231.32% increase in sales expenses, totaling ¥16,736,831.36, primarily due to increased personnel costs[12] Return on Investment - The weighted average return on equity rose to 12.00%, an increase of 8.63% from 3.37% in the previous year[6] - Investment income saw a remarkable increase of 968.75%, reaching ¥1,111,314.53 compared to a loss of ¥127,921.46 in the previous year[12]

Financial Performance - The company reported a net loss attributable to shareholders of 287.23 million yuan in 2022, primarily due to intense competition in the edible mushroom industry and losses from the king oyster mushroom project, along with high unit costs from some subsidiaries[5]. - The company recognized asset impairment losses totaling 399.79 million yuan, which reduced net profit attributable to shareholders by 311.83 million yuan[5]. - The company's operating revenue for 2022 was ¥2,320,432,033.82, representing an increase of 11.93% compared to ¥2,073,128,958.07 in 2021[39]. - The net profit attributable to shareholders of the listed company for 2022 was ¥287,226,615.66, a decrease of 7.82% from ¥308,903,523.86 in 2021[39]. - The net cash flow from operating activities increased by 50.43% to ¥367,133,291.06 in 2022, compared to ¥246,748,489.61 in 2021[39]. - The total assets at the end of 2022 were ¥4,072,032,071.35, a decrease of 6.12% from ¥4,340,128,930.93 at the end of 2021[39]. - The basic earnings per share for 2022 was -0.59 yuan, an improvement of 18.06% from -0.72 yuan in 2021[39]. - The company reported a quarterly operating revenue of ¥671,087,676.15 in Q4 2022, with a net profit attributable to shareholders of -¥293,458,103.55[42]. Business Operations - The company's main business remains the research, cultivation, and sales of fresh edible mushrooms, with enoki mushrooms accounting for approximately 70% of the business[7]. - The company has a daily production capacity of 1,445 tons of edible mushrooms, with 1,070 tons from enoki mushrooms and 245 tons from king oyster mushrooms, leading the industry in China[54]. - The edible mushroom sector accounted for ¥2,291,146,561.1, or 98.74% of total revenue, with a year-on-year growth of 12.46%[72]. - The revenue from enoki mushrooms was ¥1,630,914,628.3, which is 70.28% of total revenue, showing a growth of 13.00%[72]. - The company has established six major production bases in China and is developing additional bases in Guangxi and Jiangsu, enhancing its national layout[54]. Market Challenges and Strategies - The company faces risks from declining product prices due to intensified market competition, which could impact future profitability[12]. - The company is implementing sales transformations and enhancing brand promotion to maintain market share amid competitive pressures[14]. - The company is optimizing its raw material procurement strategy to mitigate risks associated with price fluctuations of key raw materials[15]. - The company is adopting a multi-product strategy and improving production processes to reduce the impact of seasonal price fluctuations on its financial performance[18]. - The company plans to enhance its market expansion strategies and product development in response to competitive pressures and market demands[58]. Financial Management and Fundraising - The company successfully completed a private placement of shares, raising approximately 400 million yuan to improve its capital structure and financial capacity[12]. - The company is exposed to funding risks influenced by operational performance, credit policies, interest rates, and financing channels, and aims to maintain good cooperation with financial institutions to ensure smooth financing[24]. - The profit distribution plan approved by the board proposes no cash dividends or stock bonuses, with a base of 503,044,448 shares[24]. - The company has committed a total of 97,248 million CNY for investment projects, with 77,248 million CNY already utilized, achieving a utilization rate of 79.4%[103]. Research and Development - The company is investing CNY 200 million in R&D for new product development, focusing on innovative biotechnologies[194]. - The company has established partnerships with three leading research institutions to bolster its innovation capabilities and accelerate product development[199]. - The company obtained over 200 hybrids in 2022 for the development of superior strains for mushroom production[85]. - R&D investment amounted to ¥7,493,364.65 in 2022, accounting for 0.32% of operating revenue[86]. Corporate Governance - The company has a diverse board with members holding various professional backgrounds, including finance, agriculture, and law, enhancing its governance structure[135][137]. - The company is committed to enhancing its corporate governance through the election of qualified independent directors[134][137]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 6.68 million[143]. - The company has a structured approach to compensation, requiring approval from the board and shareholders for director and supervisor remuneration[141]. Social Responsibility and Sustainability - The company actively engages in social responsibility initiatives, including blood donation and support for the elderly, promoting sustainable development[186]. - The company has established precision poverty alleviation industrial parks in Guizhou and Gansu, contributing to local economic development and achieving significant social benefits[187]. - The company has prioritized employment for impoverished households, providing training and guidance to enhance labor skills, thereby improving local employment and living conditions[188]. - The company utilizes agricultural by-products in its production process, contributing to a circular economy model[186]. Future Outlook - Future outlook indicates a projected revenue growth of 20% for the next fiscal year, targeting CNY 1.8 billion[196]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence, with a budget of CNY 500 million allocated for potential deals[196]. - The company aims to achieve a gross margin of 40% in the upcoming fiscal year, up from 35%[194]. - The company plans to control costs and improve operational efficiency by optimizing procurement processes in response to rising raw material and energy prices[114].

出席本次说明会的人员有：公司董事长、总经理杨勇萍先生，董事会秘书顾 永康先生，独立董事黄建春先生，保荐代表人聂晓春女士。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投 资 者 可 提 前 登 录"互 动 易"平台（http://irm.cninfo.com.cn）"云访谈"栏目进入公司本次年度 业绩说明会页面进行提问。届时公司将在本次说明会上对投资者普遍关注的问题 进行回答。此次活动交流期间，投资者仍可登陆活动界面进行互动提问。 欢迎广大投资者积极参与。 | 证券代码：300511 | 证券简称：雪榕生物 公告编号：2023-040 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"） 已于 2023 年 4 月 26 日在巨潮资讯网（http://www.cninfo.c ...

上海雪榕生物科技股份有限公司 投资者关系活动记录 证券代码：300511 证券简称：雪榕生物 | --- | --- | --- | |----------------|---------------------------------|----------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | 现场参观 | | | | □其他 | | | 参与单位名称及 | | 申万宏源证券（香港）有限公司 詹蔷薇 | | 人员姓名 | 群益投资信托有限公司 杨书婷 | | | 时间 | 10:30 | | | 地点 | 雪榕生物会议室 | | | 上市公司接待人 | | 董秘、副总:王向东 证券代表:靳佩臻 | | 员姓名 | 董秘助理:顾永康（记录） | | | 投资者关系活动 | Q: 请王总介绍行业及产品等情况？ | | | 主要内容介绍 | A | ：食用菌行业是微生物的一支细分行业，公司是 ...

上海雪榕生物科技股份有限公司 投资者关系活动记录 证券代码：300511 证券简称：雪榕生物 | --- | --- | --- | |----------------|-------------------------|---------------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | 现场参观 | | | | □其他 | | | 参与单位名称及 | | 国泰投信 李宗谕；野村投信 吴维；中泰证券 夏洲桐；德邦 | | 人员姓名 | | 证券 徐一阳 王力晟；东兴证券 夏立诚 张煜；国信证券 赵冰 | | | | 童；中信建投 秦基粟；群益投资 洪玉婷；海富通基金 刘海 | | | | 啸；中邮基金 黎原；兴业证券 蒋卫华 郭晓琳。 | | 时间 | 8 月 31 日 13:30 | | | 地点 | 雪榕生物一楼会议室 | | | 上市公司接待人 | 董 秘:靳佩臻 | | | 员 ...